(1) Background: This study examines frailty’s impact on proximal aortic surgery outcomes. (2) Methods: All patients with a thoracic aortic aneurysm who underwent aortic root, ascending aorta, or arch surgery from the 2016–2017 National Inpatient Sample were included. Frailty was defined by the Adjusted Clinical Groups Frailty Indicator. Outcomes of interest included in-hospital mortality and a composite of death, stroke, acute kidney injury (AKI), and major bleeding (MACE). (3) Results: Among 5745 patients, 405 (7.0%) met frailty criteria. Frail patients were older, with higher rates of chronic pulmonary disease, diabetes, and chronic kidney disease. There was no difference in in-hospital death (4.9% vs. 2.4%, p = 0.169); however, the frail group exhibited higher rates of stroke and AKI. Frail patients had a longer length of stay (17 vs. 8 days), and higher rates of non-home discharge (74.1% vs. 54.3%) than non-frail patients (both p < 0.001). Sensitivity analysis confirmed increased morbidity and mortality in frail individuals. After adjusting for patient comorbidities and hospital characteristics, frailty independently predicted MACE (OR 4.29 [1.88–9.78], p = 0.001), while age alone did not (OR 1.00 [0.99–1.02], p = 0.568). Urban teaching center status predicted a lower risk of MACE (OR 0.27 [0.08–0.94], p = 0.039). (4) Conclusions: Frailty is associated with increased morbidity in proximal aortic surgery and is a more significant predictor of mortality than age. Coordinated treatment in urban institutions may enhance outcomes for this high-risk group.
Filamin C (FLNC) variants are often associated with structural cardiomyopathies but rarely myocarditis. A 60-year-old man with newly diagnosed B-cell lymphoma and initiation of cancer therapy presented with substernal chest pain. He had experienced myocarditis 2 years ago from a COVID-19 vaccine or possible infection; however, he received another COVID-19 booster in anticipation of upcoming cancer therapy. He was diagnosed with acute myocarditis, and his course was complicated by cardiac arrest requiring multidisciplinary management. Outpatient genetic testing revealed a pathogenic FLNC variant. This report highlights the case of a patient with FLNC mutation who developed recurrent myocarditis in the setting of exogenous factors, including the COVID-19 vaccine and a history of lymphoma and immunotherapy. Myocarditis may be the initial presentation for certain genetic cardiomyopathies. Genetic testing should be strongly considered in patients with multiple episodes of myocarditis.